sulotroban has been researched along with Arteriosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bräuning, C; Hiller, E; Reinhardt, B; Riess, H | 1 |
| Hiller, E; Höfling, B; Riess, H; von Arnim, T | 1 |
1 trial(s) available for sulotroban and Arteriosclerosis
| Article | Year |
|---|---|
Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Bleeding Time; Blood Platelets; Clinical Trials as Topic; Collagen; Cyclooxygenase Inhibitors; Female; Fibrinolytic Agents; Humans; Male; Middle Aged; Platelet Aggregation; Prostaglandin Endoperoxides, Synthetic; Receptors, Cell Surface; Receptors, Prostaglandin; Receptors, Thromboxane; Sulfonamides; Thromboxane B2; Thromboxanes | 1986 |
1 other study(ies) available for sulotroban and Arteriosclerosis
| Article | Year |
|---|---|
Effects of BM 13.177, a new antiplatelet drug in patients with atherosclerotic disease.
Topics: Arteriosclerosis; beta-Thromboglobulin; Dose-Response Relationship, Drug; Fibrinolytic Agents; Humans; Male; Metabolic Clearance Rate; Middle Aged; Platelet Aggregation; Platelet Factor 4; Sulfonamides; Thromboxane B2 | 1984 |